User login
Enter your username and password here in order to log in on the website:
Keywords
- ABPA_Aspergillus
- accompanying diseases
- air-improving devices
- allergy
- animals_pets
- antibiotic therapy
- asthma
- complementary medicine
- covid-19
- diabetes
- diagnostics
- drugs side effects
- drugs under development_genetic therapy
- ENT
- general aspects
- genetics
- health care
- hepatobiliary disease
- hygiene
- i.v.-lines
- inhalation
- lung
- microbiology
- miscellaneous
- modulator therapy
- MRSA
- nutrition and GI problems
- oxygen supplementation_therapy
- physiotherapy
- Pseudomonas aeruginosa
- psychosocial
- public facilities
- recreational activities
- reproduction
- research
- social law
- sport
- swine flu_novel influenza
- transplantation
- travelling
- vaccination
- ventilation
Topics
- Last results of the phase 3 cinical trial VX661 and ivacaftor
- Hello could you inform us regarding results of the clinical phase 3 which has just ended with patients homozygous for the F508del mutation and performed by the Vertex company. Thank you
- 29.07.2014
- Phage therapy
- Ten years ago I have already sent a question to Vaincre la mucoviscidose (French CF patient organization) concerning the subject without a really satisfactory answer. While antibiotic resistance is becoming a social problem why isn't the use of phage therapy further developed, even if the results ...
- 29.07.2014
- Vaccine against Pseudomonas aeruginosa
- Hello There was a clinical trial for Pseudomonas vaccine. What are the news about this clinical trial? Are results available? Thank you.
- 29.07.2014
- F508del heterozygous- first recognitional breakthrough?
- Hello, did I get it right from the English that for the first time there has been a significant improvement in the usage combination VX-661 and KALYDECO® (Ivacaftor) in case of F508del heterozygous patients "with/independent" of G551D? That sounds like a breakthrough for the heterozygous ...
- 28.07.2014
- Drugs for delF508
- Hello, I have recently visited the annual meeting in Bad Soden, Germany. I have heard there, that Kalydeco® together with a potentiator is said to be licensed already in June 2014. Short-dated also a liquid for children is said to come on the market. Did I get this right? Does this mean the ...
- 21.07.2014
- Results from Vertex clinical trial for patient with delF508 mutation
- Hello I’m a CF patient and I’m carrying 2 different mutations: delF508 and 1717-1GA of exon 11. I would like to know if you have the results of the Vertex‘s clinical trials. Are they encouraging? If not, when will they be available? Best regards
- 14.07.2014
- Cayston®
- I’ve heard (by a service provider) about a new molecule named “Cayston®” that is used to treat CF adultes againt Pseudomonas aeruginosa. This molecule would be used with a new machine that will arrive on the market (or already has?). This person could not tell me more. I turn to you in order ...
- 14.07.2014
- VX-809 research
- Hello, in the research news dated 01.01.2013 (here the link to a German website: http://muko.info/forschung/news-detail-und-archiv/detailansicht/article/zulassungsprogramm-fuer-korrektur-des-f508del-soll-2013-starten/17.html ). it has been said, that the market authorization for "VX-809" ...
- 09.07.2014
- N30 Pharmaceuticals company
- Hello Do you have information regarding the progress of research performed on 2 molecules ((n91115 et n6022) from N30 Pharmaceuticals company? Can we have hope that this type of drug could emerge soon? Do you think that these molecules and the miglustat, based on their mechanism of action, ...
- 26.05.2014
- Amlexanox
- Dear expert team, I got aware of the following publications: http://www.ncbi.nlm.nih.gov/m/pubmed/22938201/ and http://www.google.com/patents/EP2437741A1?cl=en I would like to know if there is any data yet concerning the correction of CF nonsense mutations? Respectively, if there are any ...
- 12.05.2014